Pirtobrutinib Shows Promising Results in Patients With Heavily Pretreated Mantle Cell Lymphoma
Researchers sought to determine whether pirtobrutinib would be effective and tolerable in heavily pretreated patients with mantle cell lymphoma.
Diagnosis & Disease Information
Pegcetacoplan Superior to Eculizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria
Researchers sought to determine whether pegcetacoplan would be superior to eculizumab in treatment of low hemoglobin in patients with paroxysmal nocturnal hemoglobinuria
Prophylactic Antihemophilic Factor May Help Preserve Joint Health in Patients With Hemophilia A
Researchers sought to determine whether patients with moderate or severe hemophilia A may benefit from early prophylactic antihemophilic factor (recombinant).
DREAMM-7 Trial Examines Triplet Therapy With Belamaf for Relapsed/Refractory Multiple Myeloma
Researchers are conducting the DREAMM-7 trial to compare the safety and efficacy of belamaf plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in patients with multiple myeloma.
Nivolumab Plus Brentuximab Vedotin Shows Efficacy for Patients With Mediastinal Gray Zone Lymphoma
Researchers sought to determine whether combining nivolumab with brentuximab vedotin would be safe and effective in treating patients with mediastinal gray zone lymphoma.
Phase 3 Trial Aims To Evaluate Safety, Efficacy of Parsaclisib in Myelofibrosis
Researchers are conducting a phase 3 trial to investigate the safety and efficacy of parsaclisib and ruxolitinib vs placebo and ruxolitinib among patients with myelofibrosis who have displayed a suboptimal response to ruxolitinib only.
Fostamatinib Shows Long-Term Safety and Efficacy in Immune Thrombocytopenia, Rheumatoid Arthritis
Researchers sought to determine the long-term safety and efficacy of fostamatinib for treating patients with immune thrombocytopenia and rheumatoid arthritis.
Patients With Multiple Myeloma Receiving Belantamab Mafodotin Can Recover From Ocular Events
Researchers sought to determine whether patients with RRMM with ocular events induced by belantamab mafodotin would recover without discontinuing treatment.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...